- Previous Close
0.6800 - Open
0.6700 - Bid 0.6500 x --
- Ask 0.6700 x --
- Day's Range
0.6500 - 0.6700 - 52 Week Range
0.2600 - 1.1900 - Volume
32,500 - Avg. Volume
30,794 - Market Cap (intraday)
47.179M - Beta (5Y Monthly) -0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.03
NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. The company was founded in 2020 and is based in Toronto, Canada.
nurexone.comRecent News: NRX.V
View MorePerformance Overview: NRX.V
Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NRX.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NRX.V
View MoreValuation Measures
Market Cap
47.88M
Enterprise Value
44.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.36
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-114.31%
Return on Equity (ttm)
-253.66%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.14M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.38M
Total Debt/Equity (mrq)
0.97%
Levered Free Cash Flow (ttm)
-2.4M